However, although olaparib shows obvious advantages in the maintenance therapy for patients with PSR ovarian cancer with BRCA1/2 mutation, its high treatment cost limits its feasibility as a clinical treatment option. The gene discussed is BRCA1; the disease is ovarian cancer.